We've picked the best and the brightest in all corners of the med tech industry including major companies, startups, venture capital, industry advocates and academics. We've chosen women who represent some of the major shifts and trends within the industry such as the ever-growing consumer orientation of healthcare, the advent of cheaper, easier personalized diagnostics, the use of diagnostics to inform preventative healthcare decisions and the increasing integration of wireless technology into medical devices.
Stryker took an earnings hit during the third quarter, in part to repatriate $2 billion in cash for acquisitions and to establish an EU regional headquarters in Amsterdam, where it has moved some intellectual property. The IP transfer is expected to reduce its effective tax rate from an expected 22% in 2014 to 20% next year.
The orthopedics giant reported net earnings per share of $0.16, a 41% decline from the same quarter a year prior. It attributed the decline not only to a tax rate of about 5% on the $2 billion to be repatriated and the EU headquarters, but also to currency exchange, charges related to product recalls as well as to acquisition and restructuring-related charges.
Boston Scientific won CE-mark approval for a new suite of MRI-friendly pacemaker products, boosting its product offerings and furthering its plan of revitalizing sales for its sluggish cardiac unit.
The Marlborough, MA-based company snagged a regulatory OK for its Accolade pacemaker system with ImageReady technology, a feature that includes a programmable MRI timer and that allows patients to undergo higher energy scan MRIs. Boston Scientific also scored European regulatory approval for its Visionist and Valitude CRT-Ps, devices that provide targeted left ventricle pacing and could improve patient response to cardiac resynchronization therapy (CRT), the company said in a statement.
POPULAR COMMENT THREADS
Philips shed as much as 4% in early trading as continued manufacturing problems and intellectual property litigation as well as weakness in Russia and China weighed on investor confidence after it reported third-quarter results.
Dexcom won FDA approval for its next-generation mobile communications device for diabetes monitoring, chalking up another regulatory win and furthering the company's R&D push.
Abbott made separate announcements related to devices focused on the eyes. The first was for a deal it reached with Carl Zeiss Meditec to sell the Swiss lensmaker's cataract surgery products alongside its own ocular surgery devices.
Punctum plugs improve patient compliance and deliver drugs to the eye effectively, said the American Academy of Ophthalmology, citing the results of a Phase II study of Ocular Therapeutix's dexamethasone delivering plug, whose length is a fraction of the diameter of a dime.
Strands of DNA interlocked like Lego bricks could become the key ingredient for tomorrow's nanoscale devices, Harvard University's Wyss Institute for Biologically Inspired Engineering says.
St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.
From Our Sister Sites
Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals in a mid-stage trial. But the drug did come through on one measure of lung function, and, upon analysis of the results, the biotech believes that could be its ticket to FDA approval.
A panel of FDA advisers voted unanimously in favor of approving Novartis' new anti-inflammatory treatment, an expected positive outcome for the company as it races to be first in line among what promises to be a crowded field.